CN118439992A - 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 - Google Patents

2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 Download PDF

Info

Publication number
CN118439992A
CN118439992A CN202410415705.3A CN202410415705A CN118439992A CN 118439992 A CN118439992 A CN 118439992A CN 202410415705 A CN202410415705 A CN 202410415705A CN 118439992 A CN118439992 A CN 118439992A
Authority
CN
China
Prior art keywords
compound
polymorph
solvent
dsc
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410415705.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·斯摩林斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anzix Special Purpose Co ltd
Original Assignee
Anzix Special Purpose Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN118439992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anzix Special Purpose Co ltd filed Critical Anzix Special Purpose Co ltd
Publication of CN118439992A publication Critical patent/CN118439992A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202410415705.3A 2017-09-07 2018-09-07 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 Pending CN118439992A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
US62/555,390 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE
CN201880069894.6A CN111278808B (zh) 2017-09-07 2018-09-07 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880069894.6A Division CN111278808B (zh) 2017-09-07 2018-09-07 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式

Publications (1)

Publication Number Publication Date
CN118439992A true CN118439992A (zh) 2024-08-06

Family

ID=65517772

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410415705.3A Pending CN118439992A (zh) 2017-09-07 2018-09-07 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
CN201880069894.6A Active CN111278808B (zh) 2017-09-07 2018-09-07 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880069894.6A Active CN111278808B (zh) 2017-09-07 2018-09-07 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式

Country Status (15)

Country Link
US (4) US10669236B2 (enExample)
EP (1) EP3679016B1 (enExample)
JP (3) JP2020533412A (enExample)
KR (2) KR102691700B1 (enExample)
CN (2) CN118439992A (enExample)
AU (2) AU2018330163B2 (enExample)
BR (1) BR112020004419A2 (enExample)
CA (1) CA3074831A1 (enExample)
DK (1) DK3679016T3 (enExample)
FI (1) FI3679016T3 (enExample)
IL (1) IL272992A (enExample)
MX (2) MX2020002622A (enExample)
SG (1) SG11202001868RA (enExample)
TW (1) TWI815820B (enExample)
WO (1) WO2019051147A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
EP1390377B1 (en) * 2001-05-22 2006-03-08 Pfizer Products Inc. New crystal form of azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
DK1836169T5 (da) 2004-12-28 2023-10-09 Atnx Spv Llc Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP2008522983A (ja) * 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
DK2041071T3 (da) * 2006-06-29 2014-09-01 Kinex Pharmaceuticals Llc Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
EP2436382A1 (en) * 2006-09-28 2012-04-04 Merck Sharp & Dohme Corporation Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2015069217A1 (en) 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
BR112019018687A2 (pt) 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica

Also Published As

Publication number Publication date
SG11202001868RA (en) 2020-03-30
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
TW201920160A (zh) 2019-06-01
TWI815820B (zh) 2023-09-21
EP3679016A4 (en) 2021-09-29
JP2020533412A (ja) 2020-11-19
IL272992A (en) 2020-04-30
MX2020002622A (es) 2020-10-01
JP2025131661A (ja) 2025-09-09
US20220098152A1 (en) 2022-03-31
MX2023001805A (es) 2023-03-13
BR112020004419A2 (pt) 2020-09-08
EP3679016B1 (en) 2025-11-05
EP3679016A1 (en) 2020-07-15
KR20240119192A (ko) 2024-08-06
CN111278808B (zh) 2024-04-26
CN111278808A (zh) 2020-06-12
AU2023201010A1 (en) 2023-03-23
AU2018330163A1 (en) 2020-03-26
CA3074831A1 (en) 2019-03-14
AU2018330163B2 (en) 2023-02-02
JP2023157909A (ja) 2023-10-26
US11230527B2 (en) 2022-01-25
WO2019051147A1 (en) 2019-03-14
US20250115555A1 (en) 2025-04-10
RU2020112539A (ru) 2021-10-08
US20200255380A1 (en) 2020-08-13
KR102691700B1 (ko) 2024-08-02
FI3679016T3 (fi) 2025-12-12
RU2020112539A3 (enExample) 2022-04-19
DK3679016T3 (da) 2025-12-15
US20190071402A1 (en) 2019-03-07
US10669236B2 (en) 2020-06-02
AU2023201010B2 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
CN102510855A (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
US20250115555A1 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
WO2013028495A1 (en) Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
CN107427503A (zh) 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
TWI870440B (zh) 活化素受體樣激酶抑制劑之鹽及晶體形式
CN118139863A (zh) 单酰基甘油脂肪酶抑制剂的结晶形式
US12030886B2 (en) Form of ponatinib
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
WO2022099442A1 (zh) 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
CN102666528A (zh) 晶体cdc7 抑制剂盐
US20210395232A1 (en) Co-crystal forms of selinexor
CN116887818A (zh) 口服固体剂量制剂
JP2019116445A (ja) スルホンアミド化合物の結晶形
HK1234747B (zh) 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts
HK1262794B (en) Crystalline forms of quinolone analogs and their salts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115548

Country of ref document: HK